Abstract
Streptococcus pneumoniae (Pnc) is a major cause of morbidity and mortality in children and the elderly worldwide. When classified by its polysaccharide capsule, Pnc has >95 serotypes, each capable of causing disease. However, the invasiveness varies by serotypes. Diseases caused by pneumococcus include severe infections, such as meningitis and bacteremia (both regarded as invasive pneumococcal disease; IPD), pneumonia, and other milder mucosal diseases, such as middle ear infection (otitis media) and sinusitis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Atkinson W, et al., editors. Epidemiology and prevention of vaccine-preventable diseases. CDC Pink Book. 11th ed. Washington DC: Public Health Foundation; 2009. p. 217–30.
Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clin Infect Dis. 2014;59(12):1724–32.
Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect. 2009;15(Suppl 3):16–20.
Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14(3):e197–209.
Navarro Torné A, et al. European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era. Vaccine. 2014;32(29):3644–50.
Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children – use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1–18. ► http://ecdc.europa.eu/en/publications/Publications/0701_TER_Use_of_pneumococcal_polysaccharide_vaccine.pdf
O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902.
Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381(9862):214–22.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Dagan, R., Ben-Shimol, S. (2017). Pneumococcal Vaccines. In: Vesikari, T., Van Damme, P. (eds) Pediatric Vaccines and Vaccinations. Springer, Cham. https://doi.org/10.1007/978-3-319-59952-6_21
Download citation
DOI: https://doi.org/10.1007/978-3-319-59952-6_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-59950-2
Online ISBN: 978-3-319-59952-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)